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1. Introduction
Bladder cancer is one of the most common urinary neoplasms in industrialized countries,
with more than 50,000 new cases diagnosed annually in Europe and North America [1,2]. In
most countries of the Western world, transitional cell carcinomas (TCCs) account for 90% of
the malignancies of this organ, while 5% are identified as squamous cell carcinomas and 2%
as adenocarcinomas [3]. Approximately 80% of TCCs are low-grade tumors that are papil‐
lary, non-invasive and usually superficial, with stages Ta and Tis; the remaining 20% are
high-grade papillary or non-papillary tumors that are often invasive or metastatic, with
stages T1–T4. The five-year survival rate for TCC patients is 50%. The involvement of the
bladder muscular wall signifies a worse prognosis and requires aggressive medical inter‐
vention such as radical cystectomy [4,5].
Occupational exposures in the textile and tire industries were the first factors implicated in
the induction of bladder cancer. Currently, the prolonged use of phenacetin analgesics, ex‐
posure to cyclophosphamide, and smoking are the main risk factors associated with the eti‐
ology of transitional cell carcinoma [6]. Although men are 3-4 times more likely to develop
bladder cancer, women present more often with advanced disease and have a lower proba‐
bility of survival [7]. According to Shariat et al.[8], age is also considered a risk factor for
urothelial carcinoma because the incidence of this cancer increases progressively with age;
the incidence is higher after 60 years and peaks at 70 years, when the risk is 2% to 4% in men
and 0.5% to 1% in women [9].
© 2013 Salvadori and da Silva; licensee InTech. This is an open access article distributed under the terms of
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Clinically, the main problem associated with urothelial tumors is their highly unpredictable
potential to progress to muscle-invasive disease, become multifocal and recur [5,10]. The re‐
currences might be de novo lesions that are different from recidivates, which occur because
of incomplete resection of the primary tumor. After resection and/or treatment of a primary
tumor, de novo TCC occurs in 50% to 70% of patients over a period of 4–5 years of follow-up.
In fact, it has been suggested that patients undergoing surgical procedures are at a high risk
for developing new neoplasia and are also susceptible to recurrences, possibly because of
the presence of urothelial genetic instabilities [11-13].
Two hypotheses have been proposed to explain the association between urothelial carcino‐
genesis, multifocality and recurrence. The first hypothesis suggests a monoclonal origin of
the lesions. In other words, multifocal or recurrent tumors originate from a single trans‐
formed cell that proliferates and colonizes other parts of the bladder through intraepithelial
migration or transportation by urine. The second hypothesis proposes a polyclonal origin,
suggesting that urine carcinogens that are in contact with multiple sites lead to the develop‐
ment of independent multifocal tumors [14,15]. The understanding of the clonality of multi‐
focal bladder tumors is important to establish therapeutic strategies because new therapies
often target specific molecules in these tumors [10].
2. DNA mutation and bladder carcinogenesis
Tumors are made up of billions of cells that originate from an initial cell that eluded apopto‐
sis, accumulated genetic alterations and multiplied clonally [16]. It is expected that both ex‐
ternal and internal factors contribute to these genetic mutations. External factors include
lifestyle, such as excessive alcohol consumption, an unhealthy diet, exposure to excessive
sunlight and chemical carcinogens, lack of exercise and smoking [17]. Internal factors in‐
clude gene mutations, changes in the hormonal and immune systems, and metabolic abnor‐
malities. During cell division, spontaneous genetic errors occur at an estimated frequency of
approximately 10−5 to 10−6 [18]. Therefore, the blockade of apoptosis can favor the accumula‐
tion of mutated cells, a critical event in cancer pathogenesis [19].
Carcinogenesis is a multistep process that involves initiation, promotion and progression.
Initiation is characterized by the formation of a preneoplastic cell resulting from an irre‐
versible genotoxic event (gene mutation) caused by chemical, physical or biological carci‐
nogens.  This  mutation  usually  occurs  in  genes  that  control  the  cell  cycle,  cell
differentiation,  apoptosis  and DNA repair,  leading  to  the  survival  of  cells  with  genetic
alterations [20].  The promotion stage involves the selective clonal expansion of the initi‐
ated cell through an increase in cell growth or a decrease in apoptosis, leading to an ac‐
cumulation of  mutations  and an increase  in  the  level  of  genetic  instability  (genetic  and
epigenetic  changes)  [20].  The  third  step,  progression,  involves  genetic  events  such  as
changes  in  ploidy and chromosome integrity  and results  in  a  change  from the  preneo‐
plastic  state  to  the neoplastic  state,  producing cells  with a  high degree of  anaplasia,  an
imbalance between cell  proliferation and apoptosis and self-sufficiency (e.g.,  growth and
multiplication independent of stimuli - Figure 1) [20,21].
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Figure 1. Multistep process of carcinogenesis
Urinary bladder carcinogenesis also occurs through multiple stages that are characterized
by genetic changes that reflect the malignant transformation of an initiated normal cell [22].
These changes can occur in oncogenes/protooncogenes, tumor suppressor gene, regions of
microsatellites, and cell cycle regulatory genes [23], which can trigger a framework of genet‐
ic instability characterized by a significant increase in the mutation rate (an early event in
carcinogenesis). Genetic instability can be divided into two types: the first type comprises
the insertions/deletions (basic single nucleotide changes) that result in read errors and are
often observed in microsatellite regions (microsatellite instability), and the second type com‐
prises the loss or gain of whole chromosomes or chromosome fragments (chromosomal
changes), resulting in the loss or amplification of regions of DNA that contain genes crucial
for neoplastic development [24].
Several studies have shown that many genetic and molecular alterations are involved in the
initiation and progression stages of TCC, although the mechanisms responsible for the ma‐
lignant phenotype are not completely understood. It is known that the accumulation of ge‐
netic changes, and not just a single mutation, determines the clinical behavior of TCC [25].
In fact, several studies have demonstrated the existence of numerous chromosomal changes
in neoplastic and non-neoplasic urothelial cells from patients with a history of bladder can‐
cer. The most frequent changes are polysomy of chromosomes 3, 7 and 17 and monosomy of
chromosome 9 [26-30]. Furthermore, some authors have observed that 100% of patients with
chromosome 17 loss exhibit recurrence [31]. Genetic analyses have also shown that the onco‐
genes RAS (related to recurrence), erb-B2 (related to cell survival) and EGF/EGFR (related to
recurrence and tumor progression) are the most important prognostic markers for bladder
cancer [32]. Microsatellite alterations on chromosome 9 are indicative of genomic instability
[33], but chromosome 9q segment loss (in low-grade papillary TCC), FGFR3 mutations (low
grade non-invasive tumors with low potential of progression) and the loss of TP53 function
(associated with muscle-invasive disease and metastatic potential) have also been described
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[34,35]. Additionally, some authors have reported that SOCS-1, STAT-1, BCL-2, DAPK, and
E-cadherin gene methylation are linked to tumor recurrence [36].
The TP53 tumor suppressor gene has an important role in the cellular responses to various
stress agents, including DNA damage [37,38]. After DNA damage occurs, TP53 induces the
transient or permanent blockage of cell proliferation or activates cell death signaling path‐
ways [39]. However, it has been shown that some mutations in human tumors abolish or at‐
tenuate the binding of p53 protein to its consensus DNA sequence, abolishing the
transcriptional activation of TP53 target genes and resulting in the partial or complete loss of
p53 function [40]. In fact, some studies have demonstrated that bladder tumor cells are
grouped based on their molecular alterations in the TP53 and RB signaling pathways [41].
Several mutations were found to confer new functions to mutant p53 that are independent
of the wild-type p53 [42]. These findings have several implications, including a possible het‐
erogeneous clinical phenotype depending on whether p53 itself is mutated and the site of
the mutations or whether the p53 function is indirectly modified [43]. It has been demon‐
strated that genes related to cellular communication, cell cycle, cell division, cell death, cel‐
lular component organization, cell adhesion, and cell proliferation pathways, among others,
are closely associated with the tumor grade. Although gene networks vary according to the
tumor grade, TP53 and several other genes have been frequently shown to be associated
with the malignant phenotype of bladder tumors [44]. Independent of the TP53 status, dif‐
ferences have been reported in several signaling pathways, such as the AMP kinase, JAK/
STAT3, and MAP kinase (p38 MAPK, ERK, JNK) pathways. The downregulation of the adi‐
poR1 (involved in the AMP kinase pathway), ABCA7 (involved in the ERK phosphorylation
pathway), DUSP22 (involved in the ERK and MAPK pathways), and AKAP7 (involved in
second messenger-mediated signaling events) genes was observed in cells with different tu‐
mor grades. Similarly, genes related to transcription, replication and DNA synthesis are also
differentially expressed independent of the TP53 status [44]. Additionally, no relationship
between tumor grade or TP53 status and the expression of ANLN and S100P (genes used as
progression biomarkers in some types of tumors) in TCC lines has been described [44].
In normal cells, the p53 level is regulated by the interaction of the proteins mdm2, cop1, jnk
and pirh2, which promote p53 degradation (ubiquitin/proteasome pathway) (Figure 2). Af‐
ter exposure to genotoxic or non-genotoxic stressors, the level of p53 is increased because
the interaction with mdm2 and other regulators is inhibited. Then, several modulators (kin‐
ases, acetylases, etc) activate p53 transcriptional activity. The final result of p53 activation is
either cell cycle arrest and DNA repair or apoptosis (Figure 3) [45].
Smoking is usually associated with the development of persistent clones of DNA-damaged
cells in the urothelium and may partially explain the continuous occurrence of genetically
aberrant cells in the mucosa. It is important to note that increased DNA damage has been
detected in the transitional cells of smokers and ex-smokers who are free of neoplasia and
have normal urinary bladder cell cytology [46]. Cytogenetic analyses have shown that blad‐
der tumor recurrence is associated with high levels of DNA damage, which are still present
in the normal-appearing urothelium of patients surgically treated for TCC [12]. Data suggest
that part of this damage might occur through both clastogenic and aneugenic events, as de‐
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tected by the micronucleus test (Figure 4) in TCC patients (J.P. Castro Marcondes personal
communication, July 18, 2012). The increased level of DNA damage in cytologically “nor‐
mal” cells from patients with a history of TCC has been shown to be related to the tumor
histological grade, regardless of the length of time or clinical course since resection, suggest‐
ing these cells may be new TCC precursors or subclones of a previous TCC. Based on these
data, it has been suggested that the primary tumor represents only the most obvious compo‐
nent of the disease, and several foci of secondary “reseeded” or “relocated” anomalous uro‐
thelium exist or may appear when the primary neoplasm is diagnosed [12]. Therefore, the
genetic follow-up of patients after surgery must be a routine because elevated levels of DNA
damage could predict recurrence.
Figure 2. The TP53 gene and the p53 protein. A) The TP53 locus: chromosome 17 (17p13.1); B) the p53 protein (1 -
acidic transactivation domain and mdm2 protein binding site (amino-terminus), 2 – proline-rich region and second
transactivation domain, 3 - DNA binding domain, 4 - oligomerization domain and 5 - non-specific DNA binding do‐
main that binds to damaged DNA (carboxy-terminus)) and regulators. Adapted from [45].
Cystoscopy and cytology are considered standard procedures for monitoring patients with a
history of TCC and individuals with bladder cancer symptoms (hematuria, pollakiuria and
dysuria). However, these exams have a very limited ability to detect microscopic lesions and
are subjective because they depend on the cytopathologist’s experience; therefore, these tests
have very low sensitivity for low-grade lesions [47]. It has been shown that only 61% of pa‐
tients with biopsies positive for TCC had a similar diagnosis based on the cytological analy‐
sis [48]. On the other hand, some authors have reported 100% agreement between biopsies
and cytogenetic analysis results using probes for the centromeres of chromosomes 3, 7 and
17 and the 9p21 locus. Thus, the use of techniques that increase the sensitivity and specifici‐
ty of early TCC detection, both in patients undergoing bladder tumor resection and in pa‐
tients considered at risk for TCC, must be taken into consideration. In this context,
biomarkers linked to the behavior of a particular biological entity (e.g., chromosome dam‐
age) might be used to assess cancer risk in different tissues.
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Figure 3. Upstream and downstream p53 activation pathways. Adapted from [45].
Figure 4. Exfoliated urothelial cell with a micronucleus (arrow). Giemsa stain (X 1000). Adapted from [49].
3. Bladder cancer and chemotherapy
It is import to know the disease stage to effectively plan the treatment for bladder cancer.
Different types of treatments are available, including surgery, biologic therapy, radiothera‐
py, and chemotherapy. TCC has been efficiently treated with radiotherapy and combina‐
tions of different antineoplastic compounds. Intravesical Bacillus Calmette Guérin (BCG)
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instillations have shown success as adjuvant treatment for patients with intermediate and
high risk non-muscle-invasive bladder tumor [50]. BCG induces a massive influx of cyto‐
kines and inflammatory cells into the bladder wall and lumen [51]. Moreover, BCG therapy
has been demonstrated to reduce the recurrence rate and the risk of progression to muscle
invasive disease in patients with carcinoma in situ and superficial bladder tumors [52].
Combined chemotherapy protocols have been extensively studied with the goal of improv‐
ing bladder cancer treatment and the overall survival rate [53]. The standard protocol in‐
cludes the drugs methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) [54], but
gemcitabine has also been successfully introduced [55]. The primary effect induced by these
drugs is DNA damage with consequent cell cycle arrest and apoptosis. However, tumor
cells have different levels of sensitivity to therapeutic agents, which may affect treatment
success. Moreover, the genetic background of each tumor/patient must be taken into ac‐
count to ensure treatment efficacy. In the context of developing chemotherapy protocols, the
characterization of genes associated with a tumor’s sensitivity to antitumor agents plays a
critical role in the selection of the optimal treatment [56].
In 2000, Von der Maase et al. [54] demonstrated that the gemcitabine/cisplatin regimen had
an efficacy similar to that of the MVAC protocol but with superior safety and tolerability,
thus providing a potential standard alternative to treat bladder cancer. Gemcitabine is a de‐
oxycytidine analog, which is phosphorylated to yield an active dFdCTP metabolite (gemci‐
tabine triphosphate) that is incorporated into DNA, causing DNA strand breaks and thereby
eliciting a DNA damage response characterized by cell cycle arrest in the G1/S phase and
replication blockage [57,58]. Gemcitabine can also be incorporated into RNA to inhibit RNA
synthesis [59]. Because of its low molecular weight of 299 Da, (lower than the molecular
weights of drugs commonly used in intravesical chemotherapy; e.g., mitomycin C and dox‐
orubicin), gemcitabine is able to penetrate the bladder mucosa, which has beneficial effects
on the treatment of invasive bladder cancers [60]. Cisplatin is one of the most potent antitu‐
mor agents, with the ability to induce DNA crosslinking and apoptosis [61,62]. A molecule
of cisplatin consists of a central atom of platinum surrounded by two chlorine atoms and
two ammonia groups. Cisplatin is activated by the reaction of water molecules with the
chloride ions. This activated compound than reacts with DNA, RNA, proteins and phospho‐
lipid membranes [63]. Similar to other platinum compounds, cisplatin forms DNA adducts
between adjacent guanines (65%) and between guanine and adenine (25%) and forms inter‐
strand crosslinks (10%) that interfere with DNA replication and repair, contributing to its
antitumor efficacy [64,65].
The TP53 status had been shown to play a pivotal role in the response to a large panel of
anticancer drugs. Numerous studies have investigated the relationship between the tumor
suppressor protein p53 and/or TP53 gene mutations and the response to chemotherapy.
Cote et al. [66] demonstrated that the presence of a normal functional TP53 is associated
with a good response to chemotherapy, and Hall et al. [67] suggested that the existence of
TP53 allelic variants indicates a complex role for the TP53 pathway in human neoplasias.
Therefore, differences among TP53 responses may reflect the complex biology of this gene
with respect to the regulation of apoptosis and cell proliferation. Because the TP53 network
Genetic Instability in Normal-Appearing and Tumor Urothelium Cells and the…
http://dx.doi.org/10.5772/53502
7
is linked to many other cellular pathways, it is possible that defects in some of these path‐
ways might qualitatively or quantitatively interfere with p53 function. Moreover, p53 is only
one component of a giant surveillance network modulated by many other elements, includ‐
ing negative (Mdm2, Mdmx, Pirh2 and COP1) [68] and positive (DERP6) [69] regulators of
p53, other members of the p53 family and several other signaling pathways [70].
The TP53 and p53 status have also been used as biological markers to predict the response
to chemotherapy. However, p53 expression and BCG response have shown contradictory re‐
sults in literature. While some authors have concluded that p53 expression is not suitable as
a marker to predict BCG response [71,72], other have stated that p53 has potential to be used
as an independent marker to distinguish BCG responders and BCG non-responders in terms
of time to recurrence and progression and progression to muscle invasive disease [73,74].
Moreover, independent on TP53 status, some investigators have reported that the BCG ther‐
apy induces cellular reactive oxygen species and lipid peroxidation in cancer cells, inducing
DNA damage, which could lead to mutations that select for their survival [75]. Thus, the au‐
thors suggest that reducing either the number of instillations of BCG that patients receive or
the dose of BCG may reduce the amount of ROS and DNA damage and could lead to re‐
duced disease progression [75]. Other authors have conclude that BCG response depend on
the combination of markers to provide important information for selecting patients for the
appropriate treatment [76].
On the other hand, there are few data in the literature regarding the relationship between
this biomarker and the response to gemcitabine or cisplatin [77-80]. With regard to cell cycle
kinetics, gemcitabine or combined treatment with gemcitabine plus cisplatin induces G1 cell
cycle arrest in TCC cell lines in vitro independent of the TP53 status. Conversely, only the
cell responses to cisplatin were dependent on the TP53 status. Whereas the wild-type TP53
cells stopped in S phase, the TP53-mutated cells accumulated in G2 phase [81]. Similar find‐
ings have been described regarding apoptosis: whereas cisplatin induces apoptosis in only
wt-TP53 cells, apoptosis occurs in cells treated with gemcitabine or gemcitabine plus cispla‐
tin independent of the TP53 status, although higher percentages are observed in the wt-
TP53 cells [81]. In wt-TP53 cells, gemcitabine-induced cellular damage can stimulate p53
expression, resulting in p21 expression and cell cycle arrest, enabling DNA damage repair or
inducing apoptosis mediated by the BAX gene. In cells with a mutated TP53 phenotype, the
expression of p53 and p21 cannot be induced, but BAX can still be expressed, resulting in
apoptosis [82]. Regarding cytotoxicity, TP53-wt cells were more resistant to cisplatin and
more sensitive to gemcitabine than mutated TP53 cells [81]. Some authors have suggested
that the effect of cisplatin on human cancer cells has characteristics of senescence rather than
apoptosis [83]. According to these authors, cancer cells lacking TP53 function can also be kil‐
led via a TP53-independent mechanism, similar to replicative senescence. However, com‐
bined treatment with cisplatin and gemcitabine was more effective in reducing cell survival
than treatment with the two drugs individually, independent of the TP53 status [81]. Inter‐
estingly, genetic networks determined by Bayesian interpolation and built from microarray
data show that, in vitro, TCC cell lines do not establish positive or negative relationships be‐
tween TP53 and a group of genes but instead exhibit direct interactions between TP53 and
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many genes. Furthermore, different gene networks have been observed according to the tu‐
mor cell lines were obtained, confirming that other genes and pathways are involved in the
chemotherapy response, independent of the TP53 status [44]. It is known that both gemcita‐
bine and cisplatin act by inducing DNA structural damage and modulating gene expression.
Some authors have demonstrated that gemcitabine has cytotoxic and genotoxic effects in
murine bone marrow [84], and other authors have confirmed the genotoxic effect of antineo‐
plastic drugs in circulating blood lymphocytes [85]. Several studies revealed that cisplatin is
an effective clastogen and inducer of both sister chromatid exchange and micronuclei devel‐
opment [86,87]. Furthermore, several authors have demonstrated that cisplatin induces a no‐
ticeable mutagenic effect, increasing the frequency of micronuclei and the percentage of
chromosome aberrations in rat bone-marrow cells [88]. Additionally, Brozovic et al. [89] re‐
ported that cisplatin induces strong genotoxicity in murine peripheral blood leucocytes and
brain, liver and kidney cells. In bladder cancer cells, gemcitabine and cisplatin, alone or in
combination, have been shown to cause significant DNA damage at different tumor devel‐
opment stages independent of the TP53 status (Figure 5). However, TP53-mutated TCC cells
are more resistant to the genotoxic effects induced by the combined treatment with gemcita‐
bine and cisplatin than wild-type cells are (E.A de Carmargo personal communication, June
27, 2012). Regarding the toxicogenomic and proteomics events, Nordentoft et al. [90] dem‐
onstrated that the relationship between the transcription factor TFAP2α and cisplatin or
gemcitabine sensitivity in bladder cancer cells is dependent on p53 because TFAP2α silenc‐
ing increased the proliferation of only the wild type TP53 bladder cells and reduced cispla‐
tin- and gemcitabine-induced cell death. Additionally, Gazzaniga et al [91] reported that
gemcitabine induces apoptosis in TP53-mutated cells, involving caspase-3, -8 and -9 activa‐
tion but no changes in Bcl-2, Bax, survivin and Bcl-X expression. In fact, the gemcitabine-in‐
duced modulation of Bax expression has been observed only in a wild-type TP53 cell line
(Da Silva et al., 2012, unpublished data, [92]). In contrast, following treatment with gemcita‐
bine or cisplatin plus gemcitabine, there was an observable upregulation of the GADD45A
and CDKN1A genes independent of the TP53 status in bladder cancer cell lines, thus provid‐
ing possible links to apoptosis and cell cycle arrest (Da Silva et al., 2012, unpublished data).
On the other hand, Cho et al [93] reported that Bcl-2 upregulation in a TP53 mutated bladder
cancer cell line contributes to the development of cisplatin resistance, and targeting this
gene with an siRNA may therefore be a potential tool to reverse cisplatin resistance. Matsui
et al [94] also reported that the expression of the galectin-7 gene could serve as a candidate
predictive marker for chemosensitivity to cisplatin in wild-type TP53 cells.
In conclusion, while there is evidence implicating the role of TP53 in the regulation of DNA
repair and apoptosis and as a molecular node, other target genes can also be modulated by
antineoplastic compounds and influence the success of drug therapy. Regardless of tumor-
associated TP53 mutations or the tumor grade, simultaneous treatment with cisplatin and
gemcitabine is an effective protocol for transitional cell carcinomas. In this context, because
high concentrations of cisplatin are toxic to humans, the use of low concentrations of cispla‐
tin and gemcitabine in combination might be clinically relevant in reducing the secondary
effects of chemotherapy [81].
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Figure 5. Genotoxic damage induced by cisplatin and gemcitabine in transitional carcinoma cells, as depicted by the
comet assay. (A) Untreated cells; (B) cells treated with cisplatin; (C) cells treated with gemcitabine. Ethidium bromide
staining (X 400).
4. Actual scenario
Most cellular components exert their functions by interacting with other components locat‐
ed within the same cell, in different cells, or even in different organs. In humans, the com‐
plexity of the interaction networks (the human interactome) is impressive: there are
approximately 25,000 protein-coding genes, approximately 1,000 metabolites and an indefi‐
nite number of distinct proteins and functional RNA molecules. Therefore, the number of
cellular components capable of being regulatory interactome centers exceeds 100000 [95].
Moreover, the intra- and inter-cellular connectivity implies that the impact of genetic abnor‐
mality is not restricted to the activity of the gene product but can have effects on other genes
and their products that might have no defect. Several authors have suggested that the dis‐
ease phenotype is rarely a consequence of abnormalities in a single gene product but reflects
various patho-biological processes that interact in a complex network [96]. Therefore, the ef‐
fects of cell interconnection on disease progression can lead to the identification of genes
and systems that offer better targets for drug development. Moreover, the potential use of
microRNA in the future therapeutic interventions has also been discussed. For example, the
effects of miR-100 on cell growth and clonogenic capacity in TCC cell lines emphasize a pos‐
sible link between this miRNA and bladder carcinoma pathogenesis [97]. These new con‐
cepts may identify more accurate biomarkers for monitoring the functional integrity of
networks and classifying diseases [96].
Changes in gene expression profiles may be immediate and more sensitive markers of drug
toxicity than markers that are typically analyzed in toxicity tests (morphological changes,
carcinogenicity and reproductive markers) [98]. Furthermore, some authors have shown
that the implementation of proteomic platforms for the identification of novel targets of in‐
terest (membrane antigens, protein overexpression, etc.) is gaining widespread attention.
The incorporation of biomarkers in clinical proteomics studies has also become important to
define biologically effective therapeutic protocols for each patient and type of disease [99].
Thus, studies comparing gene and protein expression can confirm and emphasize the im‐
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portance of using different technologies to understand and characterize complex biological
systems.
5. Final conclusion
In this chapter, we presented data that demonstrate that high levels of DNA damage in nor‐
mal-appearing urothelium are associated with tumor recurrence in patients treated for blad‐
der TCC. Furthermore, the identification of genes associated with the sensitivity of tumors
to chemotherapeutic drugs may play an important role in selecting the most efficient treat‐
ment protocol. Therefore, biomarker identification is relevant not only for diagnostic accura‐
cy and prognosis but also for cancer therapy.
Currently, the ability of genomics and proteomics techniques to identify biomarkers and in‐
crease our understanding of complex cellular networks has been demonstrated. Thus, high-
throughput methodologies help characterize diseases and increase our understanding of
tumor progression mechanisms and the chemotherapy results. It is known that the primary
effects of antineoplastic drugs are linked to DNA damage, leading to molecular events that
may result in cell cycle arrest and apoptosis, which are essential responses for the mainte‐
nance of genetic integrity and cell viability [100]. Furthermore, it is known that early detec‐
tion and treatment result in better survival rates for patients without clinical symptoms
during the early stages of carcinogenesis [101].
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